Back to School: How biopharma can reboot drug development. Access exclusive analysis here
In a 2-week, double-blind, U.S. Phase III trial in 229 patients, Indiplon-MR 15 mg significantly improved
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury